Pharma Blog Watch

FavId Shows Promise for relapsed NHL patients (The Pharm Voice)
In her blog, Gloria Gamat discusses Favrille's recently announced results of a Phase II trial of its non-Hodgkin's lymphoma (NHL) drug FavId.